Novavax (NVAX) Tops Q4 EPS by 2c
Get Alerts NVAX Hot Sheet
EPS Growth %: +72.1%
Financial Fact:
Interest income: 554K
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $5.45 million.
As of December 30, 2016, the company had $235.5 million in cash and cash equivalents and marketable securities compared to $230.7 million as of December 31, 2015. Net cash used in operating activities for the full year 2016 was $255.5 million, compared to $126.1 million for same period in 2015. The increase in cash usage was primarily due to increased costs relating to our RSV F Vaccine and higher employee-related costs.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gilead Sciences (GILD) Misses Q1 EPS by 288c
- Edwards Lifesciences (EW) Tops Q1 EPS by 2c; offers guidance
- Skechers USA (SKX) Tops Q1 EPS by 23c, Beats on Revenue; Offers FY24 Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!